# Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis

> **NCT06184659** · PHASE4 · RECRUITING · sponsor: **Scandinavian Critical Care Trials Group** · enrollment: 5800 (estimated)

## Conditions studied

- Sepsis
- Septic Shock

## Interventions

- **DRUG:** Meropenem
- **DRUG:** Piperacillin/Tazobactam

## Key facts

- **NCT ID:** NCT06184659
- **Lead sponsor:** Scandinavian Critical Care Trials Group
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-26
- **Primary completion:** 2028-06-30
- **Final completion:** 2029-03-30
- **Target enrollment:** 5800 (ESTIMATED)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06184659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06184659, "Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06184659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*